stockrowRelay Therapeutics, Inc.
RLAY Healthcare Biotechnology
Relay Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.4 million, up 53.4% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- 0.00%
- Free cash flow
- +2.13%
Quarter to June 2026, against a year earlier
Follow RLAY
Alert me
Relay Therapeutics, Inc. (RLAY) Revenue growth
Relay Therapeutics, Inc.'s revenue growth over the twelve months to 30 June 2026 was −74.3%, down 127.7 percentage points from fiscal 2025 (53.4%). Over the past ten years it has ranged from −96.3% (fiscal 2021) to 2,628.8% (fiscal 2020); the current reading is higher than 67% of that period. That is below the Biotechnology industry median of 6.26% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 53.4% | 114.27 |
| FY2024 | −60.8% | (1,810.65) |
| FY2023 | 1,749.8% | 1,804.23 |
| FY2022 | −54.4% | 41.93 |
| FY2021 | −96.3% | (2,725.10) |
| FY2020 | 2,628.8% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | −95.4% | (25.42) |
| Mar 2026 | −70.0% | (700,070.02) |
| Dec 2025 | 700,000.0% | 700,097.31 |
| Jun 2025 | −97.3% | (6,450.25) |
| 12 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| ABCL AbCellera Biologics Inc. compare | 101.3% |
| IOVA Iovance Biotherapeutics, Inc. compare | 51.3% |
| TNGX Tango Therapeutics, Inc. compare | 48.3% |
| ACAD ACADIA Pharmaceuticals Inc. compare | 14.8% |
| XENE Xenon Pharmaceuticals Inc. compare | −8.15% |
| RLAY Relay Therapeutics, Inc. | −74.3% |
| PBLS Parabilis Medicines, Inc. compare | — |
| EWTX Edgewise Therapeutics, Inc. compare | — |
| IRON Disc Medicine, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on RLAY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- The full statement